Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Weber

Showing results (191-200 of 252) with videos related to

Pageof 26
Sort By:
Journal of the International AIDS Society|October 20, 2012
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyKathy Petoumenos, Signe W Worm, Eric Fontas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2012
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs studyHelen Kovari, Caroline A Sabin, Bruno Ledergerber, et al.
Journal of Virology|July 5, 2005
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptionsBeda Joos, Alexandra Trkola, Marek Fischer, et al.
AIDS (London, England)|October 4, 2008
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAntonella d'Arminio Monforte, Donald Abrams, Christian Pradier, et al.
Open Forum Infectious Diseases|March 1, 2016
Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs StudyHelen Kovari, Caroline A Sabin, Bruno Ledergerber, et al.
The New England Journal of Medicine|April 27, 2007
Class of antiretroviral drugs and the risk of myocardial infarction, Nina Friis-Møller, Peter Reiss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2022
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort StudyIsabella C Schoepf, Christian W Thorball, Helen Kovari, et al.
Nature Medicine|May 10, 2005
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesAlexandra Trkola, Herbert Kuster, Peter Rusert, et al.
Antiviral Therapy|December 15, 2010
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study, Rainer Weber, Caroline Sabin, et al.
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
Pageof 26

Showing results (191-200 of 252) with videos related to

Sort By:
Pageof 26
Journal of the International AIDS Society|October 20, 2012
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyKathy Petoumenos, Signe W Worm, Eric Fontas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 24, 2012
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs studyHelen Kovari, Caroline A Sabin, Bruno Ledergerber, et al.
Journal of Virology|July 5, 2005
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptionsBeda Joos, Alexandra Trkola, Marek Fischer, et al.
AIDS (London, England)|October 4, 2008
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAntonella d'Arminio Monforte, Donald Abrams, Christian Pradier, et al.
Open Forum Infectious Diseases|March 1, 2016
Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs StudyHelen Kovari, Caroline A Sabin, Bruno Ledergerber, et al.
The New England Journal of Medicine|April 27, 2007
Class of antiretroviral drugs and the risk of myocardial infarction, Nina Friis-Møller, Peter Reiss, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 13, 2022
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort StudyIsabella C Schoepf, Christian W Thorball, Helen Kovari, et al.
Nature Medicine|May 10, 2005
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodiesAlexandra Trkola, Herbert Kuster, Peter Rusert, et al.
Antiviral Therapy|December 15, 2010
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study, Rainer Weber, Caroline Sabin, et al.
AIDS (London, England)|May 11, 2010
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study, Colette Smith, Caroline A Sabin, et al.
Pageof 26